Replies to post #466047 on Momentum Players

[langlui]

EGTK after hours BIG news!!!!

Energtek Completes Evaluation of Gas Reservoirs in Licensed Block
Wednesday March 9, 2011, 4:44 pm

NEW YORK, March 9, 2011 /PRNewswire-FirstCall/ --

* Prospective Gas Resources of 5 Billion Cubic Feet

Energtek Inc. (Other OTC:EGTK.PK.pk - News) , a leader in hi-tech natural gas solutions and Adsorbed Natural Gas (ANG) technology, announced today that it has completed an evaluation of gas reservoirs in the licensed block in Southern Israel. The evaluation was performed following the successful production test, as reported in December 2010, of the NirAm Gas1 well.

Based on the analysis of seismic and geophysics data as well as a detailed analysis of the results of the production test, the geological team estimated that the recoverable gas resources (contingent resources) of the reservoir at which the Nir-Am Gas1 was drilled amount to 1.7 BCF (Billion Cubic Feet). In addition, the geological team identified three similar natural gas reservoirs in the Nir-Am block. Prospective gas resources from the identified reservoirs may total as much as 5 BCF.

Should these amounts be attainable, they would represent at current market prices tens of millions of dollars. The utilization of Energtek's technologies and know-how would enable the provision of the extracted gas to industrial consumers, significantly increasing the sales value of the extractable gas.

In particular, Energtek has already initiated engineering and regulatory activities for a local energy mobile supply project based on the Natural Gas reserves from the Nir-Am Gas1 well. The company has also reported that significant quantities of oil may be present at the Nir-Am block, which is officially licensed to Energtek for oil and gas exploration and exploitation.

"We are very pleased with the results of the evaluation," said Former Minister of Infrastructure and Energtek Chairman Eliezer Sandberg. "In the present economic and geopolitical conditions, it is of utmost importance to promote the utilization of every indigenous source of natural gas and oil in Israel, especially those that are close to the energy consumers. The importance of these sources in the forthcoming years cannot be overemphasized."

[megladon98_2000]

ARYX winding down w P3 two P2b and P1 trials, might

have some value.

ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with commercialized drugs in the United States. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company?s other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics was incorporated in 1997 and is based in Fremont, California.